Literature DB >> 8354632

Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group.

A Berardelli1, A Formica, B Mercuri, G Abbruzzese, A Agnoli, R Agostino, T Caraceni, F Carella, G De Fazio, D De Grandis.   

Abstract

In six Centers belonging to the Italian Movement Disorder Study Group, the efficacy of botulinum toxin treatment was evaluated in an open collaborative study in 251 patients with focal dystonia and hemifacial spasm. The percentage of functional improvement ranged from 66% to 81% in patients with blepharospasm, from 40% to 51% in patients with spasmodic torticollis and from 73% to 81% in those with hemifacial spasm. Good results were also obtained in patients with oromandibular dystonia, laryngeal dystonia and writer's cramp. Side effects were mild and transient. Local botulinum toxin injection is the first choice symptomatic treatment in focal dystonia and hemifacial spasm.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354632     DOI: 10.1007/bf02340723

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  19 in total

Review 1.  Therapeutic uses of botulinum toxin.

Authors:  J Jankovic; M F Brin
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

2.  Dose standardisation of botulinum toxin.

Authors:  N Quinn; M Hallett
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

3.  Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results.

Authors:  C M Bertrand; P Molina-Negro
Journal:  Adv Neurol       Date:  1988

4.  Carbamazepine for hemifacial spasm.

Authors:  G E Alexander; H Moses
Journal:  Neurology       Date:  1982-03       Impact factor: 9.910

5.  Management of hemifacial spasm with clonazepam.

Authors:  L Herzberg
Journal:  Neurology       Date:  1985-11       Impact factor: 9.910

Review 6.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

7.  Botulinum A toxin injection in patients with blepharospasm, torticollis and hemifacial spasm.

Authors:  A Berardelli; A Carta; F Stocchi; A Formica; A Agnoli; M Manfredi
Journal:  Ital J Neurol Sci       Date:  1990-12

8.  Botulinum A toxin injection as a treatment for blepharospasm.

Authors:  A B Scott; R A Kennedy; H A Stubbs
Journal:  Arch Ophthalmol       Date:  1985-03

9.  Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1987-04       Impact factor: 9.910

10.  Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin.

Authors:  J A Mauriello
Journal:  Neurology       Date:  1985-10       Impact factor: 9.910

View more
  6 in total

1.  Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies.

Authors:  P A Hanna; J Jankovic; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

2.  No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.

Authors:  C Lorenzano; S Bagnato; F Gilio; G Fabbrini; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 3.  Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.

Authors:  A Berardelli; G Abbruzzese; L Bertolasi; G Cantarella; F Carella; A Currà; D De Grandis; G DeFazio; G Galardi; P Girlanda; P Livrea; N Modugno; A Priori; G Ruoppolo; L Vacca; M Manfredi
Journal:  Ital J Neurol Sci       Date:  1997-10

Review 4.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

5.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 6.  Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies.

Authors:  Nicola Tambasco; Marta Filidei; Pasquale Nigro; Lucilla Parnetti; Simone Simoni
Journal:  Toxins (Basel)       Date:  2021-12-09       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.